Cardiometabolic biomarker patterns associated with cardiac MRI defined fibrosis and microvascular dysfunction in patients with heart failure with preserved ejection fraction
Heart failure with preserved ejection fraction (HFpEF) is a complex disease process influenced by metabolic disorders, systemic inflammation, myocardial fibrosis, and microvascular dysfunction. The goal of our study is to identify potential relationships between plasma biomarkers and cardiac magneti...
Saved in:
| Published in: | Frontiers in cardiovascular medicine Vol. 11; p. 1334226 |
|---|---|
| Main Authors: | , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Switzerland
Frontiers Media S.A
2024
|
| Subjects: | |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Heart failure with preserved ejection fraction (HFpEF) is a complex disease process influenced by metabolic disorders, systemic inflammation, myocardial fibrosis, and microvascular dysfunction. The goal of our study is to identify potential relationships between plasma biomarkers and cardiac magnetic resonance (CMR) imaging markers in patients with HFpEF.
Nineteen subjects with HFpEF and 15 age-matched healthy controls were enrolled and underwent multiparametric CMR and plasma biomarker analysis using the Olink® Cardiometabolic Panel (Olink Proteomics, Uppsala, Sweden). Partial least squares discriminant analysis (PLS-DA) was used to characterize CMR and biomarker variables that differentiate the subject groups into two principal components. Orthogonal projection to latent structures by partial least squares (OPLS) analysis was used to identify biomarker patterns that correlate with myocardial perfusion reserve (MPR) and extracellular volume (ECV) mapping.
A PLS-DA could differentiate between HFpEF and normal controls with two significant components explaining 79% (Q2 = 0.47) of the differences. For OPLS, there were 7 biomarkers that significantly correlated with ECV (R2 = 0.85, Q = 0.53) and 6 biomarkers that significantly correlated with MPR (R2 = 0.92, Q2 = 0.32). Only 1 biomarker significantly correlated with both ECV and MPR.
Patients with HFpEF have unique imaging and biomarker patterns that suggest mechanisms associated with metabolic disease, inflammation, fibrosis and microvascular dysfunction. |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Edited by: Emmanuel Androulakis, Royal Brompton & Harefield NHS Foundation Trust, United Kingdom Beat M. Jucker, GlaxoSmithKline, United States Reviewed by: Ashot Avagimyan, Yerevan State Medical University, Armenia Abbreviations AIF, Arterial input function, Average peak systolic circumferential strain (Average Circ SS), Average peak systolic circumferential strain rate (Average circ SSR), Average peak early diastolic circumferential strain rates (Average circ e'SR); BMI, Body mass index; BNP, B-type natriuretic peptide; CA, Carbonic anhydrase; CHL, Cell adhesion molecule; COL18A, Collagen type XVIII Alpha; DPP, Dipeptidyl-peptidase, DENSE, Displacement encoding with stimulated echoes; EFEMP, EGF-containing fibulin-like extracellular matrix protein; EF, Ejection fraction; ECG, Electrocardiogram; ECV, Extracellular volume; FETUB, Fetuin B; GIP, Gastric inhibitory polypeptide; GLP, Glucagon-like peptide; HFpEF, Heart failure with preserved ejection fraction; LV, Left ventricular; LVMI, Left ventricular mass index; LGE, Late gadolinium enhancement; KIT, Mast/stem cell growth factor receptor Kit; MET, Mesenchymal epithelial transition factor; TIMP1, Metalloproteinase inhibitor 1; MRA, Mineralocorticoid receptor antagonists; MOLLI, Modified look-locker inversion recovery; MPR, Myocardial perfusion reserve; NYHA, New York heart association; NCAM, Neural cell adhesion molecule; NPX, Normalized protein eXpression; OPLS, Orthogonal projection to latent squares; PLA, Platelet activating factor; PCR, Polymerase chain reaction; PLS-DA, Partial least squares differential analysis; CNDP, Serum carnosinase; SGLT2, Sodium-glucose-co-transporter 2; TIMD, T-cell immunoglobulin and mucin domain-containing protein; TF, Tissue function; TIMP, Tissue inhibitor of matrix metalloproteinases; TGFBR3, Transforming growth factor beta receptor type 3; UMOD, Uromodulin. These authors share first authorship Moritz Montenbruck, Katholisches Marienkrankenhaus GmbH, Germany |
| ISSN: | 2297-055X 2297-055X |
| DOI: | 10.3389/fcvm.2024.1334226 |